Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro.
Activating mutations in the NRAS gene, which occur predominantly in codon 61 (Q61R, Q61K) are among the most common genetic events in malignant melanoma. NRAS protein with oncogenic codon 61 mutations may therefore be good therapeutic targets. In the present study, we used gene expression profiling as a method for global characterization of gene expression alterations that resulted from treatment of melanoma cells with siRNA specifically targeting NRAS(Q61R). Sixteen probe sets representing 15 unique genes were identified whose expression was significantly altered by siRNA against NRAS(Q61R) in 2 melanoma cell lines. The genes with altered expression are involved in several functions, including modulation of cell growth, invasion and migration. The results suggest that downregulation of cyclin E2 and cyclin D1 and also upregulation of the negative cell-cycle regulator HBP1 in NRAS(Q61R) knockdown cells contribute to the inhibition of cell proliferation. Furthermore, suppression of oncogenic NRAS results in reduced migration and invasion, which is accompanied by downregulation of EphA2 (a receptor tyrosine kinase), uPAR (urokinase receptor) and cytoskeleton proteins such as leupaxin, paxillin and vinculin. These studies support the concept that suppression of oncogenic NRAS by siRNA can induce growth arrest and inhibit invasion of human melanoma cells by modulating the levels of these gene products.
Eskandarpour
Malihe
M
Department of Oncology-Pathology, Karolinska Institutet, Cancer Center Karolinska, Karolinska University Hospital Solna, Stockholm, Sweden. malihe.eskandarpour@ki.se
Huang
Fei
F
Reeves
Karen A
KA
Clark
Edwin
E
Hansson
Johan
J
D015815:Cell Adhesion Molecules / Q000494:pharmacology; D045744:Cell Line, Tumor; D019938:Cyclin D1 / Q000378:metabolism; D016213:Cyclins / Q000378:metabolism; D003599:Cytoskeleton / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D011905:Genes, ras; D006801:Humans; D008545:Melanoma / Q000378:metabolism*; D009154:Mutation; D015689:Oncogene Protein p21(ras) / Q000378:metabolism*; D051419:Paxillin / Q000494:pharmacology; D010641:Phenotype; D010750:Phosphoproteins / Q000494:pharmacology; D012878:Skin Neoplasms / Q000378:metabolism*; D016596:Vinculin / Q000494:pharmacology
C503688:CCNE2 protein, human; D015815:Cell Adhesion Molecules; D016213:Cyclins; C112251:LPXN protein, human; D051419:Paxillin; D010750:Phosphoproteins; D016596:Vinculin; D019938:Cyclin D1; D015689:Oncogene Protein p21(ras)